Periodic Reporting for period 2 - Vaccinesurvey (Monitor population immunity against vaccine preventable diseases)
Reporting period: 2017-01-01 to 2019-06-30
Alongside research and development objectives the project promoted mutual transfer of knowledge between academia and industry by implementing a number of staff secondments. The consortium focused on the transfer of ideas, research results and skills between researchers involved in the secondment activities. Staff secondments had been planned around the project scientific activities, therefore learning by experience (working alongside the host institution staff) and participating to scientific meetings and seminars at the host institutions was considered the best practice of transfer of knowledge within the consortium. Seconded researchers also had the opportunity to visit associated laboratories and attend international conferences and training opportunities in the host institution country.
Overall, the VaccineSurvey partnership faced a number of challenges during the 54-month long project activities that included changes and under-performance in the partnerships, experimental challenges, mobility issues, etc. The beneficiaries involved in the project have achieved most of the planned objectives with some delays and deviations that have been reported to the Commission and addressed with the best corrective measures possible within partners' reach.
The future implementation of a refined version of the assay developed by the VaccineSurvey consortium, that is an affordable, reliable and easy-to-use tool to measure the antibody response to several vaccines, could significantly help improve surveillance and outbreak control, thus enabling more programmatic and strategic plans and contributing towards a better use of government and donor-supported funds, particularly when identifying areas that may require additional resources to ensure optimal health system performance both in emergency and non-emergency situations.